Novo Nordisk A/S (NVO) Shares Sold by NorthCoast Asset Management LLC

NorthCoast Asset Management LLC reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 50.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 30,881 shares of the company’s stock after selling 31,394 shares during the period. NorthCoast Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,487,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BB&T Corp raised its holdings in shares of Novo Nordisk A/S by 14.5% in the third quarter. BB&T Corp now owns 128,300 shares of the company’s stock valued at $6,177,000 after purchasing an additional 16,202 shares during the last quarter. Willingdon Wealth Management raised its holdings in shares of Novo Nordisk A/S by 3.0% in the second quarter. Willingdon Wealth Management now owns 45,316 shares of the company’s stock valued at $1,944,000 after purchasing an additional 1,325 shares during the last quarter. Pacad Investment Ltd. acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $1,025,000. Kidder Stephen W acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $202,000. Finally, Pinnacle Associates Ltd. raised its holdings in shares of Novo Nordisk A/S by 4.9% in the second quarter. Pinnacle Associates Ltd. now owns 85,787 shares of the company’s stock valued at $3,679,000 after purchasing an additional 3,971 shares during the last quarter. Institutional investors own 6.01% of the company’s stock.

In other news, insider Eric S. Sprott bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was acquired at an average cost of $8.34 per share, with a total value of $417,000.00. 0.07% of the stock is currently owned by company insiders.

Novo Nordisk A/S (NVO) opened at $52.24 on Friday. Novo Nordisk A/S has a 52 week low of $31.91 and a 52 week high of $52.32. The firm has a market cap of $102,470.00, a price-to-earnings ratio of 22.81, a P/E/G ratio of 3.12 and a beta of 0.65.

NVO has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Tuesday, October 10th. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. BNP Paribas downgraded shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Finally, Bank of America Corporation upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a report on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $55.00.

ILLEGAL ACTIVITY WARNING: “Novo Nordisk A/S (NVO) Shares Sold by NorthCoast Asset Management LLC” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://transcriptdaily.com/2017/11/26/novo-nordisk-a-s-nvo-shares-sold-by-northcoast-asset-management-llc.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply